This finding is particularly significant given that approximately two-thirds of triple-negative patients possess proficient BRCA1 and lack homologous recombination deficiency [10,11,12]. Extensive research into combining PARP inhibitors for metastatic BC, particularly veliparib, reveals promising synergy with cytotoxic agents, enhancing effects even in tumors that are unresponsive. This evidence concerns the gene PARP1 and breast cancer.